SCYNEXIS (SCYX) announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among the five projects funded by the federal grant awarded to the new accelerator consortium led by researchers from Hackensack Meridian Center for Discovery and Innovation and the Johns Hopkins Bloomberg School of Public Health. A five-year federal grant will establish a Center of Excellence in Translational Research jointly between researchers from the Bloomberg School and the CDI, and other academic and commercial collaborators. The CETR expects to receive about $7M annually, contingent upon the availability of funds, with the support coming from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCYX:
- SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating
- SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates
- Scynexis reports Q3 EPS (17c), consensus (20c)
- SCYX Upcoming Earnings Report: What to Expect?
- Scynexis price target lowered to $3 from $4 at Guggenheim